Early Intravenous Hydrocortisone in Sepsis
Key facts
- Who runs it
- Siriraj Hospital
- Where
- Thailand1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Terminated
- People taking part
- 116 people enrolled
- Started
- 25 Jun 2024
- Ended
- 25 Apr 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Early hydrocortisone
- Normal saline placebo
- Open-label hydrocortisone
- Record updated
- 28 July 2026
- Why it stopped
- The study was terminated early on December 25, 2025, following the Data and Safety Monitoring Board (DSMB) recommendation due to preliminary evidence of futility.
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (14)Hide the full registry criteria
Who can take part
- Age of 18 years or older
- Suspected or definite sepsis Sepsis is defined by SEPSIS-3 definition as Sequential Organ Failure Assessment (SOFA) score ≥ 2 from baseline with suspected infection.2 Suspected sepsis is defined as patients with suspected infection who meet 2 or more criteria of quick SOFA (altered mentation, respiratory rate ≥ 22/min, systolic blood pressure ≤ 100 mmHg)
- Hypotension (mean arterial pressure \< 65 mmHg)
Who cannot take part
- Randomization and administration of the study drugs are not able to be executed within 3 hours after the onset of hypotension
- Immunocompromised A patient is considered immunocompromised if one of the following criteria is met: history of human immunodeficiency virus infection or acquired immunodeficiency syndrome, hematologic malignancy, receiving chemotherapy, active cancer receiving chemotherapy, current use of immunosuppressive medication)
- Received etomidate before randomization
- Received systemic corticosteroids within 4 weeks at any dose
- Cancer patients who are receiving palliative treatment
- Post-cardiac arrest
- Systemic corticosteroids indicated for other conditions
- Causes of shock other than sepsis identified
- Hyperglycemic crisis (diabetic ketoacidosis, hyperosmolar hyperglycemic state)
- Pregnancy
- Do-not-resuscitate order
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal of this clinical trial is to compare two timings of steroid treatment in patients with severe infection who develop low blood pressure.
Read full original descriptionShow less
The main question it aims to answer is:
• Which timing strategy is better between starting steroid treatment very early in the course of severe infection, or waiting until the patient does not respond to medicine that raises blood pressure according to the current guidelines?
Participants will receive either early steroid treatment or placebo right after they develop low blood pressure from infection. Both participants and treating doctors will not know which treatment participants received. When blood pressure goal is not reached after a moderate dose of drugs that raise blood pressure, an open-label steroid treatment will be given to participants as indicated in the current guidelines.
The 2 groups in the trial
- Early hydrocortisoneTreatment being tested
After randomization, low-dose hydrocortisone will be administered as soon as possible
Treatment: Early hydrocortisone and Open-label hydrocortisone
- Standard carePlacebo, for comparison
Low-dose hydrocortisone will be given when indicated according to the current Surviving Sepsis Campaign Guidelines
Treatment: Normal saline placebo and Open-label hydrocortisone
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Early Intravenous Hydrocortisone in Sepsis: a Randomized Control Trial
- Record updated
- 28 July 2026